The underlying clinical trial, registered as NCT05597020, enrolled 60 adults aged 55 or older who had endured insomnia symptoms for at least three months, scored 13 or higher on the Insomnia Severity Index, and reported at least three nocturnal voids per night. Participants were randomized in a one-to-one ratio to receive either daridorexant 50 mg or placebo for four weeks, then crossed over to the other treatment after a washout period of 14 to 21 days. This crossover design carries a distinct methodological advantage: each participant serves as their own control, which minimizes inter-participant variability and allows direct within-person comparisons of how the two treatments felt in everyday life.

What makes the new publication unusual is its commitment to the qualitative dimension of the patient experience. Alongside the validated questionnaires that formed the trial’s quantitative backbone, patients were asked open-ended, free-text questions at baseline and at the end of each treatment period. At screening, they described how insomnia and nocturia had impacted their daily lives before the study began. After each treatment month, they were asked how that impact had changed while taking the study medication. The replies were pooled into two groups, one containing responses from patients who had received daridorexant during either treatment period and the other containing responses from patients who had received placebo, and the analysis team remained blinded to treatment assignment until the coding was complete.

The analytic machinery behind the study was deliberately rigorous. Using MAXQDA version 2024, a qualitative data analysis platform, a trained analyst coded every response according to a structured codebook developed under a predefined Qualitative Analysis Plan. The codebook captured mentions of sleep, nocturia, and their impacts on physical, emotional, and cognitive functioning, activities of daily living, professional life, and relationships, with sub-codes recording whether patients described improvement, stability, worsening, or mixed change. Crucially, the themes emerged inductively from the data rather than being imposed by prior hypotheses, and no automated or AI-assisted coding was used. Regular meetings between the analyst, the research lead, and a scientific advisor resolved ambiguities, and all analytic decisions were logged to maintain consistency across the dataset.

The baseline picture that emerged was bleak and remarkably consistent. Of the 59 patients who replied at baseline, 68 percent described sleep problems, including difficulty falling asleep, staying asleep, and waking too early, while 37 percent described nocturia symptoms such as frequent nighttime voiding or incontinence. Two-thirds of replies referenced sleep issues and one-third referenced nocturia, suggesting that for these patients the insomnia itself was the more bothersome burden. But the damage extended far beyond the bedroom. Fully 83 percent of respondents commented on impacts on their lives, with 61 percent reporting negative effects on physical functioning, citing fatigue, tiredness, low energy, weakness, dizziness, and grogginess, and 52.5 percent reporting emotional tolls including frustration, irritability, stress, and nervousness. One in five described impaired cognition, and work and social life suffered as well.

After four weeks on treatment, the contrast between daridorexant and placebo was striking. Among patients taking daridorexant, 87 percent reported improvement in their sleep, compared with just 50 percent on placebo, a difference the researchers found highly significant with a p value of 0.0011. Only 10 percent of daridorexant patients said their sleep problems were unchanged, versus 40 percent of placebo patients. The nocturia findings were, if anything, more dramatic: 79 percent of patients on daridorexant reported improvement in their nighttime voiding, compared with 32 percent on placebo, a highly significant difference with a p value of 0.0013. These patient-perceived improvements align closely with the trial’s quantitative results, which showed that daridorexant increased subjective total sleep time by roughly 21 minutes and reduced nocturnal voids by an average of 1.5 episodes per night.

The benefits rippled outward into daily functioning. Improvements in quality-of-life impacts were reported by 73.7 percent of daridorexant patients who commented on impacts, compared with 46.7 percent of placebo patients. Physical functioning showed the largest gains, with 52.6 percent of daridorexant patients reporting improvement versus 26.7 percent on placebo. Cognitive functioning, activities of daily living, and emotional functioning also improved more frequently under daridorexant, with placebo patients showing no reported cognitive improvements at all. Patients described feeling less fatigued, more able to concentrate, and better equipped to manage ordinary routines that fragmented sleep had made exhausting.

Why would a sleep drug ease the urge to urinate at night? The authors offer two complementary hypotheses. The first is mechanical: by lengthening sleep duration and shortening long awakenings, daridorexant simply gives patients fewer opportunities to notice a full bladder, an explanation supported by earlier work showing that behavioral treatment of insomnia alone reduced self-reported nocturnal voids in older adults. The second is neurobiological and arguably more intriguing. The orexin system, best known for stabilizing wakefulness, also appears to influence micturition. Animal studies have shown that orexin-A activates the micturition reflex, and that blocking orexin 2 receptors restores abnormal bladder markers in models of overactive bladder. In humans, orexin antagonists may increase bladder capacity by prolonging the interval between bladder contractions. Consistent with this, orexin agonists given to people with narcolepsy have produced increased urinary urgency and frequency as expected on-target effects, the mirror image of what antagonists appear to do.

The study’s authors argue that these findings fill a genuine gap in sleep medicine. A systematic review of qualitative insomnia research identified only 22 published studies, many of which actually relied on quantitative methods, and concluded that well-conducted qualitative work in the field remains scarce compared with areas such as depression. Free-text responses complement structured patient-reported outcome measures by adding contextual depth, capturing experiences such as non-restorative sleep and mood disturbance that objective measures may miss. The longitudinal design of the survey, with baseline responses collected before treatment, also avoids the recall bias inherent in asking patients at study exit to reconstruct how they felt months earlier. And because patients were blinded to treatment and the analysts were blinded too, expectancy effects were constrained as far as the design allows.

Limitations remain, and the authors are candid about them. Responses summarized an entire month retrospectively, inviting recall bias, and the level of detail varied considerably across patients. A few replies were missing or uninterpretable, and subjective free-text data can still be shaped by placebo and expectancy effects even in a blinded crossover. Coding inevitably involves some interpretive judgment, mitigated here by a predefined analysis plan, blinded coding, and documented quality checks. The study also relied on patient history rather than polysomnography to exclude other sleep disorders. Even so, the message is compelling: patients with moderate to severe insomnia and clinically meaningful nocturia reported broad damage to their physical, emotional, and cognitive lives, and daridorexant 50 mg consistently elicited more positive patient-reported change than placebo across sleep, voiding, and daily functioning. As clinical trials increasingly seek to center the patient’s voice, this study offers a template for letting patients describe, in their own words, what treatment actually feels like.

Subject of Research: Qualitative patient-reported outcomes of daridorexant treatment in adults with chronic insomnia and comorbid nocturia

Article Title: Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial

Article References: Arnaldi, D., Bliwise, D. L., Alpan, D., Koochaki, P., Meinel, M., Olivieri, A., Rowles, R., Satapathy, A., & Lederer, K. (2026). Capturing the Patient Voice: Qualitative Assessment of Daridorexant’s Impact on Patients with Insomnia and Comorbid Nocturia from a Randomized, Placebo-Controlled Crossover Trial. Advances in Therapy. https://doi.org/10.1007/s12325-026-03803-0

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03803-0

Keywords: daridorexant, insomnia, nocturia, dual orexin receptor antagonist, patient-reported outcomes, qualitative research, crossover trial, sleep medicine, quality of life, orexin system, placebo-controlled trial, daytime functioning

The clinical case for urgency is overwhelming. Urinary incontinence fulfills every criterion of a major geriatric syndrome: it is multifactorial, exceedingly common in older populations, particularly women, and it arises from the interplay of multiple diseases, medications and functional impairments rather than from a single organ defect. Longitudinal studies have revealed that the relationships between incontinence and disability, frailty and depressive mood are bidirectional. Incontinence increases the risk of developing these conditions, and these conditions in turn raise the likelihood that incontinence will emerge over time. This feedback loop helps explain why incontinence so often marks a turning point in the trajectory of ageing, accelerating decline rather than merely accompanying it.

The consequences extend well beyond discomfort. Recent prospective cohort studies of older women recovering from hip fracture have established a bidirectional association between urinary incontinence and mobility impairment, showing that incontinence predicts death and shapes changes in living arrangements and mobility among survivors. An independent association has also been reported between incontinence and sarcopenia, the age-related loss of skeletal muscle mass and strength. Although urinary incontinence increases the risk of death, the evidence suggests that this association is largely mediated by disability, underscoring that continence and physical function are deeply intertwined. Above all, incontinence devastates quality of life, frequently burdens family caregivers and raises the probability of admission to long-term care, a finding documented in studies of families caring for older people with mild cognitive impairment and Alzheimer’s disease.

Yet despite this indisputable standing as a geriatric syndrome, urinary incontinence remains chronically underdetected, underassessed and undertreated. The authors trace the silence to multiple sources. Older people themselves often avoid seeking help because of shame and stigma, or they dismiss incontinence as a natural and therefore untreatable part of ageing. Negative attitudes and ignorance of available treatment options compound the problem. Crucially, the editorial insists that older adults are not to blame, because health care professionals frequently share the same adverse attitudes and knowledge gaps. The authors frame the issue in ethical terms: geriatricians bear a professional obligation and moral responsibility to confront the persistent stigma and neglect surrounding urinary incontinence and its related symptoms.

How, then, can the silence be uncovered? The editorial lays out a practical three-step strategy. First, awareness of urinary incontinence and its treatment options must be raised among older adults, caregivers and health professionals alike through systematic education. Second, clinicians should actively prompt patients to report symptoms rather than waiting for spontaneous disclosure; a simple question such as whether the patient has any problems with bladder or bowel function is the minimum, and it is easily feasible in routine practice. Third, validated questionnaires should be deployed systematically to identify symptoms. The International Consultation on Incontinence Questionnaire Short Form, translated into many languages, helps distinguish between specific types of incontinence in both men and women and is recommended as a dedicated screening instrument.

The need for dedicated screening is supported by comparative evidence. Although incontinence is already included in validated activities-of-daily-living instruments such as the Katz and Barthel indices, a study conducted in an acute care for elders unit found that the continence item of the Katz scale was not sensitive enough to detect urinary incontinence in hospitalized older adults, whereas the ICIQ-UI proved effective in this vulnerable and clinically complex population. The message is clear: urinary incontinence deserves a screening tool of its own, which could substantially enhance early identification and management. Once symptoms are detected, the editorial recommends comprehensive geriatric assessment, the evidence-based cornerstone of geriatric syndrome care, leading to an individually tailored management plan in which frailty and cognition are evaluated and patients and caregivers participate in decision making.

Recognizing incontinence as an integral component of comprehensive geriatric assessment carries particular diagnostic weight because of its overlap with cognitive disorders. Urinary incontinence may be an early and recognizable symptom of specific conditions including small vessel disease, frontotemporal degeneration, normal pressure hydrocephalus and dementia with Lewy bodies, whereas in Alzheimer’s disease it typically emerges in later phases as functional ability becomes increasingly compromised. Incontinence also raises the risk of falls, and the World Guidelines for Falls Prevention and Management explicitly recommend that screening for urinary incontinence and nocturia be included in multifactorial falls risk assessment. For treatment, one of the few dedicated resources is the report on incontinence in frail elderly persons from the sixth International Consultation on Incontinence. Non-pharmacological management is the first step, preserving physical function to preserve continence, and a careful medication review is essential before any pharmacotherapy, since many drugs precipitate incontinence and other bladder dysfunction through various mechanisms. Invasive procedures demand individual evaluation, because frail patients face elevated risks of complications, and much can be done even for people living with advanced dementia to preserve dignity, maintain quality of life and relieve caregiver burden.

The silence, the authors observe, reaches into research itself. Parker-Autry and Kuchel previously highlighted the disparity between knowledge accumulated on geriatric incontinence and that on falls and dementia over two decades. The editorial’s own audit of abstracts submitted to the annual congresses of the European Geriatric Medicine Society over five years found roughly 30 abstracts on urinary incontinence, compared with nearly 200 on delirium and up to 500 on falls, with only a subtle increase in recent years. The authors argue that more evidence is indeed needed, but that this gap must not preclude proper assessment and care today. They also call for reframing and broadening the concept of urinary incontinence to encompass the full spectrum of associated dysfunctions: fecal and double incontinence, which may be even more devastating and more overlooked; the combined storage and voiding symptoms of older men with benign prostatic enlargement; pelvic floor dysfunction and prolapse in growing numbers of older women; nocturia, whether as part of overactive bladder syndrome or as a multifactorial syndrome in its own right; and the underactive detrusor muscle of advanced age, which raises the risk of urinary retention and overflow incontinence. Elevated post-void residual volumes are common in acutely hospitalized older patients, and catheterization protocols need unification to prevent complications such as catheter-associated urinary tract infections.

The editorial closes with a history and a challenge. The Special Interest Group on Urinary Incontinence began in 2016 as a Task and Finish Group and produced two consensus papers on detection, diagnosis and management, yet progress in the field has been relatively slow. The authors declare that a new era must now begin, one in which geriatricians ally with multidisciplinary teams and collaborate across specialties with urogynecologists and urosurgeons, supported by promising interdisciplinary initiatives across related special interest groups. For millions of older adults, the difference between silence and a single well-asked question may determine whether a treatable condition continues to erode their dignity, independence and survival.

Subject of Research: Urinary incontinence as an underrecognized geriatric syndrome in older adults requiring improved screening, management and research

Article Title: Urinary incontinence in older adults: call for action in geriatric care and research

Article References: Nuotio, M. S., & Panourgia, M. P. (2026). Urinary incontinence in older adults: call for action in geriatric care and research. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01607-7

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01607-7

Keywords: urinary incontinence, geriatric medicine, geriatric syndromes, older adults, frailty, comprehensive geriatric assessment, falls, dementia, nocturia, screening, caregiver burden, European Geriatric Medicine Society